Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors

NCT ID: NCT07290543

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

578 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-26

Study Completion Date

2032-08-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial tests how well a web based toolkit works to improve cancer related emotional distress and anxiety in rural older cancer survivors. Rural older adults with cancer-related distress are particularly vulnerable to poorer mental health and cancer-related outcomes including increased difficulties identifying symptoms of anxiety, a reduced likelihood of knowing when to access mental health services, and a higher likelihood of having poorly managed CRD, even after receiving a psychosocial referral. The web based tool kit called CONNECT addresses digital literacy and supports for cancer-related distress management through interactive activities for setting up telehealth visits, accessing educational materials about cancer-related distress, and providing individualized mental health resource recommendations. Using CONNECT may improve cancer related emotional distress and anxiety in rural older cancer survivors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Co-design Objective (Aim 1): Finalize the CONNECT digital tool design through qualitative co-design evaluations with stakeholders to prepare the intervention for efficacy testing.

II. Efficacy Objective (Aim 2): Evaluate the efficacy of the CONNECT digital tool in reducing cancer-related distress among rural cancer survivors and caregivers, as measured by the validated 23-item Cancer and Treatment Distress Scale (CTXD), in a randomized controlled trial.

III. Implementation Objective (Aim 3): Assess the feasibility and potential for scale-up of the CONNECT intervention in rural communities and healthcare settings through qualitative interviews.

SECONDARY OBJECTIVES:

I. Assess self-reported healthcare resource utilization over the 12-month study period. (Aim 2, Efficacy Testing)

II. Assess self-reported shared device use for accessing health-related information and services. (Aim 2, Efficacy Testing)

III. Assess self-reported telehealth utilization, including portal use, completed visits, and visit modality. (Aim 2, Efficacy Testing)

IV. Evaluate cancer survivors' unmet needs using a validated 35-item unmet needs survey. (Aim 2, Efficacy Testing)

V. Evaluate caregiver strain using the validated 13-item Caregiver Strain Index. (Aim 2, Efficacy Testing)

OUTLINE: Advisory board members are assigned to arm I, patients and their caregivers are randomized to arm II or III.

ARM I: Co-design / Advisory Board Arm (Non-randomized) Advisory board members participate in qualitative co-design activities to refine the CONNECT digital tool prior to efficacy testing. Activities include small-group workshops, interviews, field-testing, and surveys focused on usability, content relevance, and acceptability of the platform.

ARM II: Intervention (CONNECT) Arm: Participants receive access to the CONNECT digital platform, which includes educational materials on cancer-related distress management, guidance on telehealth use, and personalized recommendations for supportive resources. They complete a guided onboarding tutorial with a Study Team Member, receive up to four structured review sessions (20 minutes each) by phone or video, and get automated text message reminders every two weeks for four months to encourage engagement.

Control Arm: Participants receive usual care plus a mailed educational brochure about managing cancer-related distress. They do not receive access to the CONNECT platform or coaching sessions.

ARM III: Patients are mailed an educational brochure about distress management on study. AIM 3: Scale-up / Implementation Assessment A subsample of participants from Arms II and III will participate in exit interviews to assess potential implementation outcomes, sustainability, and barriers/facilitators for scaling CONNECT in rural communities and healthcare settings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors
Study staff abstracting the data will be blinded to the participant's condition.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (Advisory board)

Advisory board members complete small group workshops, interviews and surveys on study.

Group Type EXPERIMENTAL

Interview

Intervention Type OTHER

Complete interview

Interview

Intervention Type OTHER

Complete small group workshop

Survey Administration

Intervention Type OTHER

Ancillary study

Arm II (CONNECT platform)

Patients and their caregivers receive access to the CONNECT platform, which includes educational materials on distress management, guides to telehealth and personalized recommendations for resources. Patients and their caregivers complete a guided tutorial of the platform with a research assistant at the start of the intervention period, receive biweekly phone calls with the research assistant, for 20 minutes starting on 14 days to 2 months to review the four cancer-related management functions and receive a text message reminders to encourage use, every 2 weeks for 4 months.

Group Type EXPERIMENTAL

Educational Intervention

Intervention Type OTHER

Receive educational materials on distress management and guides to telehealth

Internet-Based Intervention

Intervention Type OTHER

Receive access to CONNECT platform

Interview

Intervention Type OTHER

Complete interview

Patient Navigation

Intervention Type BEHAVIORAL

Receive personalized recommendations for resources

Survey Administration

Intervention Type OTHER

Ancillary study

Telephone-Based Intervention

Intervention Type BEHAVIORAL

Complete calls with research assistant

Text Message-Based Navigation Intervention

Intervention Type OTHER

Receive text message reminders

Arm III (Educational brochure)

Patients are mailed an educational brochure about distress management on study.

Group Type ACTIVE_COMPARATOR

Educational Intervention

Intervention Type OTHER

Receive written educational brochure about distress management

Interview

Intervention Type OTHER

Complete interview

Survey Administration

Intervention Type OTHER

Ancillary study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Educational Intervention

Receive educational materials on distress management and guides to telehealth

Intervention Type OTHER

Educational Intervention

Receive written educational brochure about distress management

Intervention Type OTHER

Internet-Based Intervention

Receive access to CONNECT platform

Intervention Type OTHER

Interview

Complete interview

Intervention Type OTHER

Interview

Complete small group workshop

Intervention Type OTHER

Patient Navigation

Receive personalized recommendations for resources

Intervention Type BEHAVIORAL

Survey Administration

Ancillary study

Intervention Type OTHER

Telephone-Based Intervention

Complete calls with research assistant

Intervention Type BEHAVIORAL

Text Message-Based Navigation Intervention

Receive text message reminders

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Education for Intervention Intervention by Education Intervention through Education Intervention, Educational Education for Intervention Intervention by Education Intervention through Education Intervention, Educational Patient Navigator Program Automated Text Message-Based Navigation Text Message-Based Navigation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AIM 1: Invited by a member of the study team
* AIM 1: In the following or related field:

* Healthcare professionals (physicians, nurses, pharmacists, etc.)
* Patient advocates and representatives
* Researchers in healthcare or technology fields
* Healthcare administrators and managers
* AIM 1: Must be over 18 years old
* AIM 1: English-speaking
* AIM 1: Willing and able to provide informed consent
* AIM 2 (RURAL OLDER CANCER SURVIVORS): A rural resident based on the Health Resources \& Services Administration (HRSA) rural analyzer
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Self-report of diagnosis with any cancer
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Self-report posttreatment (i.e., completion of curative intent therapy including surgery, chemotherapy, molecularly targeted, and endocrine therapy)
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Have access to a computer, a smartphone, or a tablet computer
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Aged \> 65 years old
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Assessed as having Cancer and Treatment Distress scale (CTXD) scores \> 0.85 at screening
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Have a caregiver willing to participate
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Non-institutionalized
* AIM 2 (RURAL OLDER CANCER SURVIVORS): English proficient
* AIM 2 (RURAL OLDER CANCER SURVIVORS): Willing and able to provide informed consent
* AIM 2 (CAREGIVER): An identified informal caregiver of an eligible ROCS (caregivers include, but are not limited to, a child, partner, or friend; caregivers can reside in a rural or urban area and may or may not live with the ROCS
* AIM 2 (CAREGIVER): Have internet access
* AIM 2 (CAREGIVER): ≥ 18 years old
* AIM 2 (CAREGIVER): Non-institutionalized
* AIM 2 (CAREGIVER): English proficient
* AIM 2 (CAREGIVER): Willing and able to provide informed consent
* AIM 3 (FINAL WORKSHOP): Includes providers, medical and practice managers, patient care coordinators, and medical health technologists

Exclusion Criteria

* AIM 2 (RURAL OLDER CANCER SURVIVORS): Experience a cancer recurrence or a new cancer diagnosis during their participation in the trial because of the body of literature that reports increased distress associated with cancer recurrence
* AIM 2 (RURAL OLDER CANCER SURVIVORS AND CAREGIVER): Are inpatients
* AIM 2 (RURAL OLDER CANCER SURVIVORS AND CAREGIVER): Cognitive impairment precludes the ability to provide written consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

National Institute of Nursing Research (NINR)

NIH

Sponsor Role collaborator

Northwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marquita W Lewis, PhD

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northwestern University

Chicago, Illinois, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Study Coordinator

Role: CONTACT

Phone: 312-503-1986

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marquita W. Lewis

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2024-09384

Identifier Type: REGISTRY

Identifier Source: secondary_id

STU00222660

Identifier Type: -

Identifier Source: secondary_id

NU 24CC20

Identifier Type: OTHER

Identifier Source: secondary_id

P30CA060553

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01NR021666

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NU 24CC20

Identifier Type: -

Identifier Source: org_study_id